John McNally - Concepedia

Author

John McNally

Gilead Sciences (United States)

Also Known As

JOHN J. McNALLY, JOHN MCNALLY, John J McNally, John J. McNally, John J. Mcnally, John McNally, John N. McNally

Publications

8.8K

Citations

H-Index

Concepts

All Affiliations

Gilead Sciences (United States)Johns Hopkins University Goethe University Frankfurt UNSW Sydney Casa Sollievo della Sofferenza

About

John McNally is an author at Gilead Sciences (United States) specializing in medicine, hepatitis, and viral hepatitis.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	12	12	1.3K
2	Engineering	1	1	20
3	Health Sciences	1	1	95
4	Natural Sciences	1	1	63
5	Biochemistry	1	1	63

John McNally

Publications

8.7K

Citations

H-Index

Page 1

	Year	Citations
Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection Eric Lawitz, Alessandra Mangia, David Wyles, New England Journal of Medicine	2013	1.8K
Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection Jordan J. Feld, Ira M. Jacobson, Christophe Hézode, New England Journal of Medicine	2015	1.1K
Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options Ira M. Jacobson, Stuart C. Gordon, Kris V. Kowdley, New England Journal of Medicine	2013	1.1K
Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection Graham R. Foster, Nezam H. Afdhal, Stuart K. Roberts, New England Journal of Medicine	2015	845
Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis Michael P. Curry, Jacqueline G. O’Leary, Natalie Bzowej, New England Journal of Medicine	2015	795
Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial Brian G. Feagan, Silvio Danese, Edward V. Loftus, The Lancet InflammationChronic Inflammatory DiseasesFunctional Gastrointestinal DisorderPhase 2B/3Gastroenterology	2021	415
T0070907, a Selective Ligand for Peroxisome Proliferator-activated Receptor γ, Functions as an Antagonist of Biochemical and Cellular Activities Gary Lee, Fabienne Elwood, John McNally, Journal of Biological Chemistry	2002	319
Concordance of sustained virological response 4, 12, and 24 weeks post‐treatment with sofosbuvir‐containing regimens for hepatitis C virus Eric M. Yoshida, Mark Sulkowski, Edward Gane, Hepatology	2014	195
The Incidence of Microbial Keratitis among Wearers of a 30-Day Silicone Hydrogel Extended-Wear Contact Lens Oliver D. Schein, John McNally, Joanne Katz, Ophthalmology KeratoconusOphthalmologyContact DermatitisMicrobiologyMedicine	2005	185
Sofosbuvir and Velpatasvir for the Treatment of Hepatitis C Virus in Patients Coinfected With Human Immunodeficiency Virus Type 1: An Open-Label, Phase 3 Study David Wyles, Norbert Bräu, Shyam Kottilil, Clinical Infectious Diseases	2017	156

Page 1